

**STEM CELLS AND TISSUE ENGINEERING IN
TREATMENT OF PEDIATRIC
GASTROINTESTINAL DISORDERS**

Essay

Submitted for Partial Fulfillment of Master
Degree In pediatrics

By

Ibrahim Ezz El Regal Shamah
M.B., B.Ch. (2001), Tanta University

Under Supervision of

Prof. Dr. Hoda Lotfy Elsayed

Professor of Pediatrics
Faculty of Medicine
Ain Shams University

Dr. Marwa Talaat Eldeeb

Lecturer of Pediatrics
Faculty of Medicine
Ain Shams University

*Faculty of Medicine
Ain Shams University
2010*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ
صَلَّى الْعَظِيمِ

سورة البقرة الآية (32)

ACKNOWLEDGEMENT

First, I have to express my sincere thanks to our merciful, and great Allah, as without his support, I wouldn't have achieved anything, and I hope this work will be accepted.

I would like to express my deepest gratitude, respects and thanks to ***Professor Doctor Hoda Lotfy Elsayed***, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for great support, valuable assistance and constant encouragement.

I would also like to express my sincere feelings of gratitude and thanks to ***Doctor Marwa Talaat Eldeeb***, Lecturer of Pediatrics, Faculty of Medicine, Ain Shamas University, for devoting a lot of precious time, her continuous supervision, effort and guidance.

Also, my deepest gratitude to my family specially my parents for their great assistance, effort, help and support who didn't save time or effort to help me.

Finally, I can't forget my wife, my daughter ***Mennah***, and my son ***Ahmed***, my God bless them and keep them safe to me.

List of contents

Subject	Page
1-Acknowledgement	
2-List of contents	i
3-List of tables	ii
4-List of figures	iii
5-List of abbreviation	v
6-Introduction and aim of the work	1
7-Stem cells (definition, characteristics and classification)	6
8-Embryonic stem cells	17
9-Fetal stem cells	33
10-Neonatal stem cells	36
11-Adult stem cells:	41
o Hematopoietic stem cells	45
o Mesenchymal stem cells	61
o Gastrointestinal stem cells	66
12-Stem cells as a therapeutic treatment option	79
13Pediatric Gastrointestinal Disorders Where Stem cells show promise:	94
i. Inflammatory bowel syndrome	94
ii. Celiac disease	111
iii. Necrotizing entocolitis	123
iv. Hirschsprung disease	135
v. Short bowel syndrome	147
14-Summary	161
15-Referances	167
16-Arabic Summary	—

List of Tables

Table No.	Title	Page
Table 1	Properties of ES cells	32
Table 2	Properties of Adult SCs	44
Table 3	Disease commonly treated with HSCs transplantation	53
Table 4	Celiac disease's clinical manifestations ..	116

List of Figures

Figure number	Title	Page
Figure 1	Origin of stem cells	9
Figure 2	Stem cells can be derived from embryonic, fetal, neonatal, and adult tissues	16
Figure 3	Methods to reprogram adult human cells	20
Figure 4	Schematic diagram showing the possible differentiation pathways of ESCs	27
Figure 5	Hematopoietic and Stromal stem cell differentiation	43
Figure 6	Mesenchymal stem cells common sources and multilineage differentiation .	65
Figure 7	Schematic view of a Crypt of Lieberkuhn	70
Figure 8	Putative intestinal stem cell niche	73
Figure 9	Diagrammatic representation of the gastric unit or gland	76
Figure 10	Diagram summarizing the origin and differentiation program of parietal cells	78
Figure 11	Stem Cell Paracrine Properties	88

Figure 12	Schematic representation of normal and IBD mucosal tissues	96
Figure 13	Pathophysiology of necrotizing enterocolitis	126
Figure 14	Different populations of stem cells as cell-based therapies for disorders of ENS	147
Figure 15	Schematic illustration of the processes involved in intestinal tissue engineering and some of the possible for uses for the engineered	160


List of Abbreviations

AEA	Anti-endomysial.
AFS	Amniotic fluid stem.
AGA	Antigliadin antibodies.
APC	Adenomatous polyposis coli
ASC	Adult stem cell.
ASCs	Adult stem cells.
ASCA	Anti-Saccharomyces cerevisiae antibody
bFGF	Basic fibroblast growth factor.
BM	Bone marrow.
BM-SC	Bone marrow-derived stem cell.
BMP	Bone morphogenic protein.
CD	Cluster of differentiation.
CDAI	Chrohn's Disease Activity Index.
CNS	Central nervous system.
CD	Crohn's disease
Cy	Cyclophosphamide
DCAMKL-1	Doublecortin and Ca M kinase-like-1
EB	Embryoid body.
ECL	Entero-chromaffin-like
EG	Embryonic germ
EGF	Epidermal growth factor.
EGFR	Epidermal growth factor receptor.
ENS	Enteric nervous system.
ENSC	Enteric neural stem cell.
ES	Embryonic stem
ESC	Embryonic stem cell.
ESCs	Embryonic stem cells.
epiSC	Epiblast stem cell.
FACS	Fluorescent activated cell sorting

FGF	Fibroblast growth factor.
FSCs	Fetal stem cells.
G-CSF	Granulocyte- colony stimulating factor
GISCs	Gastrointestinal stem cells.
GLP-2	Glucagon-like peptide-2
GM-CSF	Granulocyte-macrophage- colony stimulating factor.
G-MRI	Gadolinium-enhanced magnetic resonance imaging
GVHD	Graft-versus-host-disease.
GVL	Graft versus leukemia.
HGF	Hepatocyte growth factor.
HLA	Human leukocytic antigen.
HSC	Hematopoietic stem cell.
HSCs	Hematopoietic stem cells.
HSCR	Hirschsprung disease.
HSCT	Hematopoietic stem cell transplantation.
IBD	Inflammatory bowel disease.
ICM	Inner cell mass.
I-FABP	Fatty acid binding protein in the intestine.
IGF	Insulin like growth factor.
IGFBPs	Insulin like growth factor binding proteins.
Ihh	Indian hedgehog.
IL-3	Interleukin-3.
IL-6	Interleukin-6.
IL-8	Interleukin-8.
iPS	Induced pluripotent stem.
ISCs	Intestinal stem cells.
IVF	In vitro fertilization.
KGF	Keratinocyte growth factor.
L-FABP	Fatty acid binding protein in the liver.
Lgr5	Leucine-rich-repeat-containing G-protein-coupled receptor 5.

LIF	Leukemia inhibitory factor.
ME	Middle Eastern.
MEF	Mouse embryonic fibroblast.
MEFs	Mouse embryonic fibroblasts.
MHC	Major histocompatibility antigens.
MNCF	Mononuclear cell fraction.
MSC	Mesenchymal stem cell.
MSCs	Mesenchymal stem cells.
NA	North African.
NC	Nack cell.
NEC	Necrotizing enterocolitis.
NESC	Neuroepithelial stem cells.
NK	Natural killer.
NLB	Neurosphere like body.
NSC	Neural stem cell.
OmpC	Escherichia coli outer membrane-porin.
pANCA	perinuclear antineutrophil cytoplasmic antibodies
PBSC	Peripheral blood stem cells.
PC	Parietal cell.
PN	Parenteral nutrition.
PSC	Pluripotent stem cell.
PTEN	P-phosphatase and tensin homologue.
RCD	Refractory Celiac Disease.
SC	Stem cell.
SBS	Short bowel syndrome.
SCNT	Somatic cell nuclear transfer.
SCT	Stem cell transplantation.
SIS	Small intestinal submucosa.
TBI	Total body irradiation.
TGF-β	Transforming growth factor – β.
Th1	T helper cell 1

Th2	T helper 2
TNF	Tumour necrosis factor.
tTG	Tissue transglutaminase.
UC	Ulcerative colitis.
UCB	Umbilical cord blood.
VEGF	Vascular endothelial growth factor.
VLBW	Very low birth weight.
WJMSCs	Wharton's jelly mesenchymal stem cells.
ZCs	Zymogenic cells.



INTRODUCTION

AND



AIM OF THE WORK

Introduction

The human body comprises over 200 different cell types that are organized into tissues and organs to provide all the functions required for viability and reproduction. Historically, biologists have been interested primarily in the events that occur prior to birth. The second half of the twentieth century was a golden era for developmental biology, since the key regulatory pathways that control specification and morphogenesis of tissues were defined at the molecular level (**Arias, 2008**).

In recent years, there has been an explosion of interest in stem cells, not just within the scientific and medical communities but also among politicians, religious groups and ethicists. The origins of stem cell research lie in a desire to understand how tissues are maintained in adult life, rather than how different cell types arise in the embryo. An interest in adult tissues fell, historically, within the remit of pathologists and thus tended to be considered in the context of disease, particularly cancer (**Watt and Driskell, 2010**).

It was appreciated long ago that within a given tissue there is cellular heterogeneity: in some tissues, such as the blood, skin and intestinal epithelium, the differentiated cells have a short lifespan and are unable to self-renew. This led to

the concept that such tissues are maintained by stem cells, defined as cells with extensive renewal capacity and the ability to generate daughter cells that undergo further differentiation. Such cells generate only the differentiated lineages appropriate for the tissue in which they reside and are thus referred to as multipotent or unipotent (**Watt and Driskell, 2010**).

New therapies, based on stem cell transplantation or endogenous stem cells, are emerging areas, as is drug discovery. Haematopoietic stem cell transplantation is the oldest stem cell therapy and is the treatment that is most widely available (**Austin et al., 2008**).

Also, the extensive proliferation and differentiation capacities of stem cells make them optimal for seeding tissue engineered grafts (**Satija et al., 2007**).

Furthurmore, the release of protective factors (paracrine effects) has also been shown to be beneficial to ischemic tissues (**Wang et al., 2008**).

Pediatric gastrointestinal disorders such as inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC) are concerning sources of patient morbidity and mortality within the pediatric community. Medical management of these diseases is often suboptimal, and surgical resection of the diseased intestine may be warranted (**Markel et al., 2006**).

In any cases, however, surgical resection leaves the patient with an inadequate length of small intestine that precludes normal nutrient and fluid absorption. These patients may therefore require long term parenteral nutritional support due to short bowel syndrome (SBS) (**Goulet and Ruemmele, 2006**).

Moreover, parenteral nutrition increases the risk for developing parenteral nutrition-associated liver failure (**Lloyd and Gabe, 2007**).

Research is underway to understand the mechanisms associated with the intestinal ischemia and inflammation, bacterial translocation, sepsis, and organ failure that frequently go hand-in-hand with these disorders (**Markel et al., 2008**).

Stem cell therapy might protect injured native intestine by promoting neovascularization, while also facilitating intestinal restitution following the removal of the injuring stimulus (**Aicher et al., 2007**).

There were several reports indicated that bone marrow derived stem cells located in the injured gastrointestinal tract and contributed to its regeneration by differentiating into functional epithelia cells or infusing with the gastrointestinal stem cells. Although the concept of cell-based therapy for various diseases of the gastrointestinal tract is widely accepted,